Form 8-K - Current report:
SEC Accession No. 0001651308-24-000164
Filing Date
2024-12-10
Accepted
2024-12-10 06:02:43
Documents
14
Period of Report
2024-12-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20241209.htm   iXBRL 8-K 39515
2 EX-10.1 a20241210formxcmbloanxex10.htm EX-10.1 253390
  Complete submission text file 0001651308-24-000164.txt   464676

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20241209.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20241209_lab.xml EX-101.LAB 21545
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20241209_pre.xml EX-101.PRE 12484
16 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20241209_htm.xml XML 2866
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 241537006
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)